CP-866087 FUNDAMENTALS EXPLAINED

Contraindicated (1)bortezomib will increase the degree or impact of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Powerful or moderate CYP2C19 inhibitors might improve mavacamten systemic exposure, resulting in coronary heart failure due to systolic dysfunction.Consequently, there is a good scaled-down right isosceles